Sangamo Therapeutics (SGMO)

Apr 4, 2025, 2:57 PM EDT - 16 days ago

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

Apr 3, 2025, 4:01 PM EDT - 17 days ago

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Mar 17, 2025, 6:29 PM EDT - 4 weeks ago

Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 4:01 PM EDT - 4 weeks ago

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 4:05 PM EST - 6 weeks ago

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Feb 6, 2025, 8:05 AM EST - 2 months ago

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Jan 15, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out

Jan 14, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation

Jan 13, 2025, 10:00 AM EST - 3 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 12, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation

Jan 10, 2025, 10:00 AM EST - 3 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 9, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Investors to Connect

Jan 8, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation

Jan 7, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation

Jan 6, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect

Jan 5, 2025, 10:00 AM EST - 3 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 3, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation

Jan 2, 2025, 6:00 PM EST - 3 months ago

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Jan 2, 2025, 4:00 PM EST - 3 months ago

Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Jan 2, 2025, 3:05 PM EST - 3 months ago

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Jan 2, 2025, 10:15 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Investors to Inquire about Securities Investigation

Dec 31, 2024, 12:01 PM EST - 3 months ago

Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet

Dec 31, 2024, 11:22 AM EST - 3 months ago

Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact

PFE

Dec 31, 2024, 11:20 AM EST - 3 months ago

Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact

Dec 31, 2024, 9:14 AM EST - 3 months ago

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

PFE

Dec 31, 2024, 8:47 AM EST - 3 months ago

Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Dec 30, 2024, 4:34 PM EST - 3 months ago

Sangamo to reclaim hemophilia A therapy rights post Pfizer termination

PFE

Dec 30, 2024, 4:15 PM EST - 3 months ago

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer's Decision to Cease Development of Giroctocogene Fitelparvovec

Dec 19, 2024, 2:48 PM EST - 4 months ago

Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development

Dec 19, 2024, 2:30 AM EST - 4 months ago

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Nov 19, 2024, 4:15 PM EST - 5 months ago

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

Nov 12, 2024, 9:25 PM EST - 5 months ago

Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:01 PM EST - 5 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 4, 2024, 4:15 PM EST - 5 months ago

Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

Oct 23, 2024, 3:28 PM EDT - 6 months ago

Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development